SEC Form 4 · accession 0001209191-15-035544
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
David Pernock
Director
Period of report
Apr 21, 2015
Accepted (ET)
Apr 22, 2015 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $59.31 | Apr 21, 2015 | A | 15,000 | A | — | Apr 20, 2025 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option fully vests on April 21, 2016, subject to the reporting person's continuous service with the issuer as of the vesting date.